CohBar Inc
CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fi… Read more
CohBar Inc (CWBR) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2023: -0.190x
Based on the latest financial reports, CohBar Inc (CWBR) has a cash flow conversion efficiency ratio of -0.190x as of June 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.80 Million) by net assets ($9.50 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
CohBar Inc - Cash Flow Conversion Efficiency Trend (2011–2022)
This chart illustrates how CohBar Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
CohBar Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CohBar Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Retail Food Group Limited
PINK:RFGPF
|
0.000x |
|
Genix Pharmaceuticals Corporation
OTCQB:GENPF
|
0.049x |
|
TronicS Microsystems SA
PA:ALTRO
|
-0.435x |
|
Capitol Nusantara Indonesia
JK:CANI
|
0.005x |
|
BAINS MER MONAC N
MU:RJ8
|
N/A |
|
Australian Pacific Coal Ltd
AU:AQC
|
2.588x |
|
iCoreConnect Inc. Common stock
NASDAQ:ICCT
|
0.083x |
|
PortfolioMan Lundgr Inv-China kl n EUR
CO:PMILGICHIEUR
|
N/A |
Annual Cash Flow Conversion Efficiency for CohBar Inc (2011–2022)
The table below shows the annual cash flow conversion efficiency of CohBar Inc from 2011 to 2022.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | $15.33 Million | $-10.45 Million | -0.681x | -20.77% |
| 2021-12-31 | $25.61 Million | $-14.45 Million | -0.564x | -6.66% |
| 2020-12-31 | $18.49 Million | $-9.78 Million | -0.529x | +57.41% |
| 2019-12-31 | $8.14 Million | $-10.11 Million | -1.242x | -120.23% |
| 2018-12-31 | $17.96 Million | $-10.13 Million | -0.564x | +43.72% |
| 2017-12-31 | $7.62 Million | $-7.63 Million | -1.002x | -67.52% |
| 2016-12-31 | $8.70 Million | $-5.20 Million | -0.598x | -61.64% |
| 2015-12-31 | $9.81 Million | $-3.63 Million | -0.370x | +52.82% |
| 2014-12-31 | $1.07 Million | $-838.97K | -0.784x | -103.29% |
| 2013-12-31 | $-29.60K | $-705.53K | 23.835x | +1523.26% |
| 2012-12-31 | $830.00K | $-1.39 Million | -1.675x | -200.29% |
| 2011-12-31 | $520.00K | $-290.00K | -0.558x | -- |